User Fee Obligations: FY 2011 ADUFA Financial Report
User fees are expended only for costs necessary to support the process for the review of animal drug applications, as defined in ADUFA. Allowable and excludable costs for the process for the review of animal drug applications are described in Appendix D.
In FY 2011, FDA obligated $16,632,800 from animal drug user fees. Table 2 provides a breakout of user fee obligations by expense category during the past two fiscal years.
Animal Drug User Fee Obligations By Expense Category
As Of September 30, 2011
Other includes expenses from categories such as rent payments to others, printing & reproduction, and other miscellaneous expenses.
EXPENSE CATEGORY FY 2010 FY 2011 Personnel Compensation and Benefits $9,380,664 $9,890,135 Travel and Transportation $363,912 $403,782 Rent $659,000 $671,800 Communications $41,265 $37,297 Contract Services $5,080,690 $4,638,973 Equipment and Supplies $997,485 $924,531 Other  $77,684 $66,282 TOTAL OBLIGATIONS $16,600,700 $16,632,800
FDA dedicated 197 FTEs to the process for the review of animal drug applications in FY 2003, before ADUFA was enacted. In FY 2011, ADUFA fees and appropriations paid for a total of 289 FTEs, 92 more FTEs than were used in FY 2003 for the review process. Employee salary and benefits paid from user fees in FY 2011 totaled approximately 59 percent of the obligations from user fees. FDA is working to strengthen and expand its capacities to conduct efficient and timely reviews, and to ensure the safety and effectiveness of new animal drugs.
See the section Total Cost Of The Process For The Review Of Animal Drug Applications, on page 10, for more discussion on the total process costs for the review of applications for new animal drugs.